
Induction therapy with obinutuzumab plus bendamustine or obinutuzumab plus CHOP, followed by obinutuzumab maintenance, is associated with tolerable safety and promising efficacy in patients with follicular lymphoma

GAUDI was a non-randomized trial

Untreated patients with follicular lymphoma allocated to one of the two induction chemotherapy backbones on a per-center basis



Progression free survival rate at 36 months

Induction therapy

Maintenance therapy

patients with

end-of-treatment response

Grigg et al., Haematologica, 2017